自身免疫性肝炎患者血清白细胞分化抗原38和白细胞介素21水平变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2022.06.017

摘要/Abstract

摘要： 目的探讨应用血清白细胞分化抗原38(CD38)和白细胞介素21(IL-21)水平判断自身免疫性肝炎(AIH)患者肝组织炎症活动度的效能。方法 2018年10月～2021年10月我院收治的53例AIH患者,进行临床病情分度,均接受肝活检。采用ELISA法检测血清CD38和IL-21水平。采用单因素分析影响AIH患者病情的因素,对影响AIH患者病情的因素进行Logistic回归分析,应用受试者工作特征曲线(ROC)分析应用血清CD38和IL-21水平判断AIH患者肝组织炎症活动度的效能。结果 19例重度患者血清总胆红素、ALT、AST、CD38、IL-21、存在肝硬化比率和肝组织汇管区淋巴细胞浸润占比分别为(89.4±15.2)μmol/L、(179.3±36.5)U/L、(216.1±37.6)U/L、(19.0±4.5)pg/mL、(367.8±62.0)pg/mL、36.8%和84.2%,显著高于34例轻中度患者【分别为(36.5±6.8)μmol/L、(61.2±25.9)U/L、(78.7±33.8)U/L、(11.1±2.3)pg/mL、(209.5±46.2)pg/mL、8.8%和5.9%,P<0.05】;23例肝组织G3～G4患者血清CD38和IL-21水平分别为(21.8±4.4)pg/mL和(387.1±59.7)pg/mL,显著高于30例肝组织G1～G2患者【分别为(12.4±2.3)pg/mL和(194.6±45.5)pg/mL,P<0.05】;多因素Logistic回归分析显示血清总胆红素、CD38和IL-21水平及肝组织汇管区淋巴细胞浸润均是影响AIH患者肝组织炎症活动严重的独立危险因素(P<0.05);经ROC分析显示,分别以血清CD38和IL-21水平为20.4 pg/mL和379.3 pg/mL为截断点,联合判断AIH患者肝组织炎症活动严重的AUC为0.939,其灵敏度和特异度分别为82.6%和96.7%,显著优于任一指标的单独判断。结论 AIH患者血清CD38和IL-21水平随病情严重而升高,可以利用这一特征初步判断肝组织炎症活动度程度,值得进一步研究。

关键词: 自身免疫性肝炎, 白细胞分化抗原38, 白细胞介素21, 肝组织炎症活动度

Abstract: Objective The purpose of this study was to investigate serum peripheral blood leukocyte differentiation antigen 38 (CD38) and interleukin 21 (IL-21) level changes and their implications in patients with autoimmune hepatitis (AIH). Methods 53 patients with AIH were admitted to our hospital between October 2018 and October 2021, and all underwent liver biopsies. The patients were clinically defined to mild or moderate and severe degree of the disease. Serum CD38 and IL-21 levels were determined by enzyme-linked immunosorbent assay. The univariate and multivariate Logistic regression analysis were applied to analyze the factors affecting the intrahepatic tissue inflammatory activity, and the area under the receiver operating characteristic curve (AUROC) was applied to judge the diagnostic efficacy. Results Serum bilirubin, ALT, AST, CD38, IL-21 levels, the incidence of liver cirrhosis and the percentage of intrahepatic lymphocyte infiltration in portal area in 19 patients with severe degree of AIH were(89.4±15.2)μmol/L,(179.3±36.5)U/L,(216.1±37.6)U/L, (19.0±4.5)pg/mL, (367.8±62.0)pg/mL, 36.8% and 84.2%, all significantly higher than [(36.5±6.8)μmol/L, (61.2±25.9)U/L, (78.7±33.8)U/L, (11.1±2.3)pg/mL, (209.5±46.2)pg/mL, 8.8% and 5.9%, respectively, P<0.05] in 34 patients with mild/moderate AIH; serum CD38 and IL-21 levels in 23 patients with G3-G4 AIH were (21.8±4.4)pg/mL and (387.1±59.7)pg/mL, both significantly higher than [(12.4±2.3)pg/mL and (194.6±45.5)pg/mL, respectively, P<0.05] in 30 patients with G1-G2; the multivariate Logistic regression analysis showed that serum bilirubin, CD38 and IL-21 levels and intrahepatic lymphocyte infiltration in portal area were all the independent risk factors for severe liver tissue injury (P<0.05); the ROC analysis showed that the AUC was 0.939, with the sensitivity of 82.6% and specificity of 96.7% when the combination of serum CD38 (20.4 pg/mL as the cut-off-value ) and IL-21 (379.3 pg/mL as the cut-off-value) was applied to predict the intrahepatic inflammatory activity, superior to any one of the two parameter. Conclusion Serum CD38 and IL-21 levels increase in patients with autoimmune hepatitis, as the disease deteriorate, and the clinicians might predict the disease severity based on this phenomenon.

Key words: Autoimmune hepatitis, Leukocyte differentiation antigen 38, Interleukin 21, Histological activity index

居峰, 姚上志, 王栋, 叶必星, 蒋丽琳, 朱艳红. 自身免疫性肝炎患者血清白细胞分化抗原38和白细胞介素21水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(6): 824-827.

Ju Feng, Yao Shangzhi, Wang Dong, et al.. Serum peripheral blood leukocyte differentiation antigen 38 and interleukin 21 levels in patients with autoimmune hepatitis[J]. Journal of Practical Hepatology, 2022, 25(6): 824-827.

参考文献

[1] Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. Uni Eur Gastroenterol J, 2019, 7(9):1156-1163.
[2] Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol, 2021, 27(1):58-69.
[3] You Z, Li Y, Wang Q, et al. The clinical significance of hepatic CD69⁺ CD103⁺ CD8⁺ resident-memory T cells in autoimmune hepatitis. Hepatology, 2021, 74(2):847-863.
[4] Burns M, Ostendorf L, Biesen R, et al. Dysregulated CD38 expression on peripheral blood immune cell subsets in SLE. Int J Mol Sci, 2021, 22(5):2424-2432.
[5] Abe K, Takahashi A, Imaizumi H, et al. Interleukin-21 plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis. Springerplus, 2016, 5(1):777-785.
[6] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015年). 中华传染病杂志, 2016, 34(4):193-208.
[7] Brahim I, Brahim I, Hazime R, et al. Hépatites auto-immunes: diagnostic immunologique autoimmune hepatitis: immunological diagnosis. Presse Med, 2017, 46(11):1008-1019.
[8] Gaber Y, AbdAllah M, Salama A, et al. Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. Expert Rev Gastroenterol Hepatol, 2021, 15(10):1181-1189.
[9] Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatology, 2020, 72(2):671-722.
[10] Golbabapour S, Bagheri-Lankarani K, Ghavami S, et al. Autoimmune hepatitis and stellate cells: an insight into the role of autophagy. Curr Med Chem, 2020, 27(35):6073-6095.
[11] Kemme S, Mack CL. Pediatric autoimmune liver diseases: autoimmune hepatitis and primary sclerosing cholangitis. Pediatr Clin North Am, 2021, 68(6):1293-1307.
[12] Weiler-Normann C, Lohse AW. Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation. Curr Opin Gastroenterol, 2021, 37(2):86-90.
[13] Renand A, Cervera-Marzal I, Gil L, et al. Integrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis. J Hepatol, 2020, 73(6):1379-1390.
[14] Hasan MM, Thompson-Snipes L, Klintmalm G, et al. CD24hiCD38hi and CD24hiCD27⁺ human regulatory B cells display common and distinct functional characteristics. J Immunol, 2019, 203(8):2110-2120.
[15] Tang L, Chen C, Gao X, et al. Interleukin 21 reinvigorates the antiviral activity of hepatitis B virus (HBV)-specific CD8⁺ T cells in chronic HBV infection. J Infect Dis, 2019, 219(5):750-759.
[16] Liu T, Song J, Zhang M, et al. Interleukin-21 receptor gene polymorphism is associated with hepatitis B virus-related hepatocellular carcinoma in Chinese patients. J Clin Lab Anal, 2019, 33(5):2860-2869.
[17] Shoraka S, Mohebbi SR, Hosseini SM, et al. Association between interleukin-21 and interleukin-21 receptor gene polymorphisms with susceptibility to chronic hepatitis B virus infection and HBV spontaneous clearance in Iranian population. Microb Pathog, 2019, 128(3):263-267.
[18] Huang CH, Fan JH, Jeng WJ, et al. Innate-like bystander-activated CD38⁺ HLA-DR⁺ CD8⁺ T cells play a pathogenic role in patients with chronic hepatitis C. Hepatology, 2021, 10(4):339-376.
[19] Ostendorf L, Burns M, Durek P,et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med, 2020, 383(12):1149-1155.
[20] Zhou Y, Zhang Y, Han J,et al. Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. J Transl Med, 2020, 18(1):131-138.
[21] Glaría E, Valledor AF. Roles of CD38 in the immune response to infection. Cells, 2020, 9(1):228-238.
[22] Biewenga M, Heidt S, Vergunst M,et al. B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis. JHEP Rep, 2022, 4(5):1004-1012.
[23] Liang M, Liwen Z, Juan D,et al. Dysregulated TFR and TFH cells correlate with B-cell differentiation and antibody production in autoimmune hepatitis. J Cell Mol Med, 2020, 24(7):3948-3957.
[24] Noguchi F, Chu PS, Yoshida A, et al. Early dynamics of meld scores predict corticosteroid responsiveness to severe acute-onset autoimmune hepatitis. Clin Gastroenterol Hepatol, 2021, 5(21)609-616.
[25] Li Y, Yan L, Wang R, et al. Serum immunoglobulin G levels predict biochemical and histological remission of autoimmune hepatitis type 1: a single-center experience and literature review. Clin Rev Allergy Immunol, 2021, 4(7):1019-1033.

自身免疫性肝炎患者血清白细胞分化抗原38和白细胞介素21水平变化及其临床意义探讨^*

Serum peripheral blood leukocyte differentiation antigen 38 and interleukin 21 levels in patients with autoimmune hepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	严兆兰, 祖红梅, 蔡长霞, 魏巍. 血清低水平丙氨酸氨基转移酶的HBV感染者临床特征分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 343-346.
[2]	马国斌, 赵晓宏, 赵鹏, 杨冰. 自身免疫性肝炎患者肝组织IL-35表达和外周血髓样抑制细胞百分比变化临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 199-202.
[3]	徐艳, 于秉楠, 武剑. 自身免疫性肝炎和原发性胆汁性肝硬化患者自身免疫性甲状腺疾病流行率调查^*[J]. 实用肝脏病杂志, 2022, 25(1): 42-45.
[4]	史雪丽, 张万里, 毛俊, 颜悦蓉. 自身免疫性肝炎大鼠血清IL-38和β2GPI水平及其与肝组织病变的关系^*[J]. 实用肝脏病杂志, 2021, 24(6): 803-806.
[5]	肖金玉, 王延峰, 文小霞. 自身免疫性肝炎患者血清趋化因子CCL4和CXCL10水平及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(6): 827-830.
[6]	王绮夏, 马雄. 自身免疫性肝病精准诊治与临床转化研究的思考^*[J]. 实用肝脏病杂志, 2021, 24(4): 457-459.
[7]	李变利, 徐丽红. 药物性肝损伤、药物诱导性自身免疫性肝炎和自身免疫性肝炎鉴别诊断研究进展^*[J]. 实用肝脏病杂志, 2021, 24(4): 460-463.
[8]	梁玉萍, 粟全球, 张慧, 王佳林. 自身免疫性肝炎患者维生素D缺乏调查及其临床特征分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 464-467.
[9]	刘娜, 张华敏, 邓巧娟. 抑制TRAF6基因表达对自身免疫性肝炎大鼠肝组织NF-κB信号通路相关蛋白表达的影响[J]. 实用肝脏病杂志, 2021, 24(4): 468-471.
[10]	齐玫, 张瑞金, 田树萍, 于艳华. 平均血小板体积对自身免疫性肝炎患者治疗不应答的预测价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 371-374.
[11]	聂柳, 彭罕鸣, 廖东亮. 泼尼松和硫唑嘌呤联合熊去氧胆酸治疗自身免疫性肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 224-227.
[12]	李庆玲, 何树光, 易小明, 段婷娜, 周意. 雷公藤多甙联合异甘草酸镁治疗自身免疫性肝炎患者外周血淋巴细胞PD-1和PD-L1变化[J]. 实用肝脏病杂志, 2021, 24(1): 79-82.
[13]	王雨, 王楠, 王巧侠, 马清华, 潘新杰, 付建军. 利肝隆联合异甘草酸镁治疗自身免疫性肝炎患者疗效及其对血清趋化因子水平的影响^*[J]. 实用肝脏病杂志, 2020, 23(6): 821-824.
[14]	凌晶, 张友健, 宋雄峰. 自身免疫性肝炎患者血清趋化因子和GP73水平变化及其临床意义研究[J]. 实用肝脏病杂志, 2020, 23(6): 825-828.
[15]	张健荣, 顾尔莉, 王忠成, 施亚军. 自身免疫性肝炎、原发性胆汁性胆管炎及其重叠综合征患者临床特征比较^*[J]. 实用肝脏病杂志, 2020, 23(6): 829-832.